Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

4094 results

Sort By:

Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC

Study ID: NCT06681220
Start Date: 2025-06-01
End Date: 2030-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

152

Intervention / Treatment

PARP inhibitor/Temozolomide

Lurbinectedin

Sponsor

VA Office of Research and Development

Source: clinicaltrials.gov

Share:
Add to list

Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients

Study ID: NCT06704074
Start Date: 2025-05
End Date: 2026-11-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

120

Intervention / Treatment

virtual reality (VR) head mounted display

Sponsor

Qilu Hospital of Shandong University

Source: clinicaltrials.gov

Share:
Add to list

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Study ID: NCT06294548
Start Date: 2025-04-30
End Date: 2028-07-28
Study Type

Interventional

Study Phase

Phase2

No. of Participants

45

Intervention / Treatment

Formula

Atezolizumab

Infatuating

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

Prevention of Recurrence of Clostridioides Difficile Colitis with Ursodeoxycholic Acid (UCDA) As a Supplement to Standard Therapy

Study ID: NCT06884748
Start Date: 2025-05-01
End Date: 2028-05-01
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

30

Intervention / Treatment

Ursodiol 500 MG

Sponsor

Medical College of Wisconsin

Source: clinicaltrials.gov

Share:
Add to list

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Study ID: NCT06735248
Start Date: 2025-04-28
End Date: 2029-01-08
Study Type

Interventional

Study Phase

Phase2

No. of Participants

180

Intervention / Treatment

mRNA-1195

Placebo

Sponsor

ModernaTX, Inc.

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Study ID: NCT06919965
Start Date: 2025-08-25
End Date: 2032-02-05
Study Type

Interventional

Study Phase

Phase3

No. of Participants

220

Intervention / Treatment

TAR-210

Mitomycin C

Gemcitabine

Sponsor

Janssen Research & Development, LLC

Source: clinicaltrials.gov

Share:
Add to list

A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer

Study ID: NCT04381130
Start Date: 2025-09-01
End Date: 2026-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

EF-009

Sponsor

Everfront Biotech Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

Silk Bioprotein as a Wound Dressing for Double-Incision Mastectomy

Study ID: NCT06921148
Start Date: 2025-04-30
End Date: 2027-04-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

One side of chest wall with Silk bioprotein dressing. Other side of chest wall with Dermabond/Prineo dressing

Survey to plastic surgeons

Sponsor

Indiana University

Source: clinicaltrials.gov

Share:
Add to list

Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus

Study ID: NCT06428630
Start Date: 2025-05-01
End Date: 2027-09-01
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

20

Intervention / Treatment

dexamethasone oral rinse

Sponsor

Tufts University

Source: clinicaltrials.gov

Share:
Add to list

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

Study ID: NCT06606730
Start Date: 2025-07-01
End Date: 2039-06-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

2454

Intervention / Treatment

Pembrolizumab

Deescalation

Sponsor

UNICANCER

Source: clinicaltrials.gov

Share:
Add to list